Science AI Journal
Medicine · Research topic

Open research questions in Amyotrophic Lateral Sclerosis Research

50 unresolved questions extracted from the limitations and future-work sections of 232 Amyotrophic Lateral Sclerosis Research papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Although our preliminary work has shown cryptic-epitope-specific CD8+ T cells in amyotrophic lateral sclerosis (ALS) and inclusion body myositis (IBM), their presence, specificity, and functional consequences in FTD remain unknown.

    Clonally expanded cryptic-epitope-specific CD8+ T cells mediate HLA-restricted neurotoxicity in TDP-43-associated frontotemporal dementia 2267088 · 2026 · DOI

  • These pathways encompassed both well-established ALS genes, as well as six target genes--PTPRN2, UNC13C, TTC3, USP10, PSMD4, and RUFY3--of which USP10, PSMD4, and RUFY3 have not yet been described in the context of ALS genetic association studies.

    Transcriptional pathways of definitive ALS genes implicate novel disease-associated target genes · 2026 · DOI

  • A substantial fraction of amyotrophic lateral sclerosis (ALS)-associated proteins remain poorly characterized, in part because of the limited availability of validated research antibodies.

    A validated antibody toolbox for ALS research · 2026 · DOI

  • Astrocytes are key mediators of non-cell-autonomous neurodegeneration in ALS, but whether they undergo disease-associated phenoconversion in C9orf72 expansion carriers remains unclear.

    Astrocyte dysfunction distinguishes monozygotic twin C9orf72 expansion carriers discordant for amyotrophic lateral sclerosis. · 2026 · DOI

  • Amyotrophic lateral sclerosis (ALS) is increasingly understood as a progressive neurodegenerative disorder with distributed cortical and subcortical involvement, but in vivo metabolic mapping has been limited by the spatial coverage of single-voxel proton magnetic resonance spectroscopy (MRS).

    Glutamine and NAA dissociate in ALS across somatotopically defined motor regions using 7T MRSI · 2026 · DOI

  • The G protein-coupled receptor GPR17 is a critical regulator of oligodendrocyte maturation and has emerged as a candidate target in ALS, yet its relevance to human disease and its therapeutic potential remain unclear.

    Selective targeting of the oligodendroglial GPR17 receptor improves myelin integrity and motor function in female SOD1G93A mice · 2026 · DOI

  • Substantial work has begun to elucidate the mechanisms contributing to pathology in FTD/ALS, including disruptions to RNA localization, neuronal transport, and local translation. We expect the field will con- tinue to expand upon recent developments in identifying zipcode regions, localization motifs, and RBP interactomes to better characterize the local transcriptome and its disruption in disease states. Furthermore, while the roles of RBPs, C9orf72, and the RQC in translational control in FTD/ALS are strongly supported, their direct interactions with trans- lation machinery could be further explored. Lastly, we expect future research to closely study the mechanisms yielding toxic phase transi- tions, LLPS, and modulation by PTMs, and testing proposed methods targeting them. Correcting these and other disruptions by targeting mutations or proteinopathies in relevant RBPs, C9orf72 mutations and toxic DPRs, and NIRs, posttranslational modifications, and other reg- ulators of phase transitions may offer promising targets for desperately needed therapies. The strong evidence supporting roles for neuronal transport and translation in FTD/ALS makes the topic a compelling candidate for future research. Diving deeper into the mechanisms described here and building upon current translational work may form a crucial foundation informing future therapeutic development.

    Dysregulated neuronal mRNA transport and translation in FTD/ALS · 2026 · DOI

  • While these findings implicated ARF1-GAP dysregulation in ALS/FTD and supported ARF1 suppression as potential intervention, small molecules that modulate ARF1-CSW interactions are lacking.

    Small molecules targeting ARF1 interaction with C9orf72:SMCR8:WDR41 complexes suppress its overactivation implicated in ALS/FTD · 2026 · DOI

  • Speech‑derived measures have shown promise for capturing bulbar decline with greater sensitivity, but their neurobiological correlates remain unclear.

    Thinning of the oral motor cortex is linked to impaired speech in amyotrophic lateral sclerosis · 2026 · DOI

  • Cutaneous changes in ALS remain an underexplored interface between dermatology and neurodegeneration and may hold potential for earlier diagnosis, disease monitoring and stratification.

    P48 Cutaneous biomarkers of amyotrophic lateral sclerosis: a systematic review · 2026 · DOI

  • Progranulin (PRGN), an anti-inflammatory glycoprotein involved in various autoimmune diseases, has rarely been studied as a diagnostic biomarker for infectious arthritis.

    Diagnostic accuracy of synovial fluid progranulin vs. C-reactive protein in septic arthritis: a comparative biomarker study · 2026 · DOI

  • The identification of ANXA11 mutations in FTLD/ALS has expanded the genetic landscape of multisystem pro- teinopathies [8, 36, 37]; however, the cellular mecha- nisms linking ANXA11 aggregation to neuronal death and progressive spreading remain elusive.

    Lysophagy protects against ANXA11 amyloid fibril toxicity and propagation in FTLD · 2026 · DOI

  • Yet, whilst recent studies have characterised the cell biological consequences of NEK1 loss-of-function, the biochemical effects of ALS-associated missense variants on kinase activity have not been directly investigated.

    NEK1 autophosphorylation is disrupted by amyotrophic lateral sclerosis-associated missense variants: activity biomarkers and structural insights · 2026 · DOI

  • Introduction: Frontotemporal dementia (FTD) comprises heterogeneous neurodegenerative syndromes with limited data from low- and middle-income countries, where diagnostic delay and misdiagnosis are common.

    Clinical presentation and diagnostic challenges of frontotemporal dementia in Brazil: A 15-year cohort study. · 2026 · DOI

  • The MTHFR C677T (rs1801133) variant, known for reducing enzymatic activity in the folate cycle, has been implicated in ALS risk, though findings remain inconsistent across diverse populations.

    Enhanced Genetic Vulnerability to Amyotrophic Lateral Sclerosis: Insights from a Case–Control Study on the MTHFR C677T Variant in a Brazilian Population · 2026 · DOI

  • ALS and other MNDs are severely neglected in Africa, imposing a substantial burden on patients and their caregivers and families. In this Review, we have highlighted the wide variations in annual MND frequencies between the different African regions, with relatively high case frequencies in Egypt and South Africa, where more focused care is available for people with neuromuscular diseases. However, the case frequencies in Africa remain below those found in well-resourced settings. The younger ages at MND onset across the continent are associated with lower levels of education and reduced life expectancy compared with the Global North. This observation suggests that poverty influences case detection and diagnosis of MND in a region where socioeconomic factors create barriers to accessing the limited number of neurologists. These factors might introduce bias whereby individuals with slowly progressing MND are more likely to be detected and followed-up in hospital-based settings. Globally, Southern Africa has the highest HIV prevalence, and in this region the number of people living with ALS plus HIV infection matches the expected frequency of people living only with HIV. A critical review of case reports suggesting a link between HIV and ALS showed that most of the illustrative cases were questionable, and in many instances the diagnosis of ALS could be refuted. Nevertheless, HIV infects the nervous system early after exposure, and prompt initiation of ART seems to reduce the risk of many neurological syndromes. Currently, no data are available regarding the impact of comorbid HIV infection on MND progression, even if HIV infection is well controlled on ART, and further research is required in this area. Gene-based therapies for MND are generating considerable enthusiasm, and African cohorts are keen to contribute to the global effort in appropriate gene-based trials. Therefore, participation of Africa in the global quest to better understand the genetic basis of MND is crucial. Of the limited number of young patients with MND of African ancestry who have undergone comprehensive genetic testing, only a few have been shown to harbour pathogenic variants in known ALS-associated genes, highlighting the need to include African individuals living with MND in genomics research. Epidemiologists anticipate a rise in cases of MND in Africa over the next decade. Although access to therapies is an important future goal, utilization of palliative care practitioners to improve care for both patients and families should already be achievable in many parts of Africa. Furthermore, patients diagnosed with MND who are living in remote or rural regions might benefit from follow-up virtual consultations with experienced neurologists who could provide advice, guidance, and support for them and their families as the disease advances. This Review represents a call to action for all possible stakeholders including neurologists, researchers, governmental agencies, funders and drug developers to change the landscape for people living with MND in resource-limited settings such as Africa. Initial steps could include raising awareness of MND in Africa and the realization that a listening, caring clinician can be a powerful provider of comfort while the community awaits the arrival of accessible therapies for this devastating disease. The global MND community is starting to recognize Africa as a previously neglected region, and innovative approaches to seed funding and fostering of international partnerships are now required to turn this goodwill into action (Box 2).

    Motor neuron disease in Africa: a critical appraisal of the literature · 2026 · DOI

  • 1Neurology Research Group, Department of Medicine and Neuroscience Institute, University of Cape Town, Cape Town, South Africa. 2Department of Neurology, University College Hospital, Ibadan, Nigeria. 3Division of Neurology, Department of Neurosciences, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 4Department of Medicine, Medical College of East Africa (Nairobi Campus), Aga Khan University, Nairobi, Kenya. 5Clinical Omics and Informatics Unit, Neuroscience Institute, University of Cape Town, Cape Town, South Africa.

    Motor neuron disease in Africa: a critical appraisal of the literature · 2026 · DOI

  • Several limitations should be stated clearly. The studies by Cheung [26-29] are recent and should be treated as hypothesis-generating. Their claims require independent validation and functional follow-up before they can be considered established. Because the framework relies heavily on author-derived works, there is a risk of circular hypothesis reinforcement. The evidence-grade table (Table 1) is intended to make that risk explicit, but it does not remove it. Independent replication by groups without intellectual investment in the model is essential. Secondly, the four-tier model simplifies complex biology into a mesoscale neural- network framework. Although it reproduces broad clinical trajectories, it cannot capture all molecular interactions, cell-type dynamics, or circuit heterogeneity present in human ALS. Thirdly, TWAS studies identify associations between genetically predicted gene expression and disease risk. They do not prove causality. The pathway-level signals reported in the studies by Cheung [26-29] are consistent with the proposed model, but they require functional testing in cellular and animal systems. Colocalization, fine- mapping, independent replication, and cell-type-specific validation would be needed before causal interpretation. Fourthly, large longitudinal datasets that combine clinical measures, molecular markers, imaging, pruning- related markers, NAD+ metabolites, autophagy flux, and circuit connectivity are not yet available at the scale needed to test the three-state model directly. Prospective studies will be needed to evaluate the timing and order of the proposed transitions. Fifthly, the model maps symptoms to broad circuit domains, but real neural networks are highly interconnected. Treating compartments as partly separable is a useful heuristic, yet it may not fully capture the distributed nature of ALS pathology. Future versions of the framework will need to represent network-level interactions more explicitly. Keeping these limitations in mind, it should be noted that the present framework does not replace established ALS evaluation, genetic testing where indicated, respiratory monitoring, multidisciplinary care, or evidence-based treatment. Its intended use is to generate falsifiable research questions. As such, it should not be used to make diagnostic, prognostic, or therapeutic decisions. It should also be noted that while the recent sulforaphane study in methylmercury-induced ALS-like pathology [55] is useful because it supplies external preclinical evidence touching Nrf2, HO-1, SIRT1, inflammatory, apoptotic, myelin, neurofilament, and systemic markers, toxin-induced ALS-like pathology is not the same as sporadic ALS, SOD1-ALS, C9orf72 ALS/FTD, or other genetic forms. Its findings should not be extrapolated to human treatment without additional disease-relevant models and clinical trials.

    Symptom-Level Precision Neurology in Amyotrophic Lateral Sclerosis (ALS): Linking Microglial Pruning, Mitochondrial Nicotinamide Adenine Dinucleotide (NAD+) Compensation, and Autophagy Failure Across the Aging Spectrum · 2026 · DOI

  • Conclusion The NeuraSpeech represents a significant advancement in speech-based ALS diagnosis, achieving 97.2% diagnostic accuracy with remarkably low variance (±1.0%). Through the integration of multi-modal feature extraction, ensemble machine learning, and blockchain technology, we have addressed critical challenges in ALS diagnosis including diagnostic delays, lack of objective biomarkers, data privacy concerns, and limited accessibility to specialized care. The optimal selection of 22 features spanning traditional acoustic measures, deep learning embeddings, nonlinear dynamics, and multiresolution analysis captures complementary aspects of speech pathology in ALS, resulting in robust performance across diverse patient populations. The blockchain integration using Hyperledger Fabric provides essential infrastructure for secure, auditable, and privacy-preserving diagnostic processes. With a transaction throughput of 28.3−54.7 TPS and latencies less than 2 s, the system demonstrates practical viability for clinical deployment. Patient-controlled data sharing mechanisms and cryptographic integrity verification establish trust in AI-generated diagnoses while maintaining compliance with healthcare regulations. 6.2 Limitations Despite these promising results, several limitations must be acknowledged. The most significant limitation of this study is the absence of external validation on an independent dataset from a different healthcare institution. Audio-based diagnostic models are particularly vulnerable to overfitting site-specific characteristics including recording equipment (smartphones with standard headsets in the Minsk cohort), acoustic environments, background noise profiles, sampling rates, analog-to-digital conversion characteristics, and regional speech patterns or dialectal variations. While Neuraspeech: a secure machine learning-blockchain framework for speech-based amyotrophic lateral sclerosis…1 3 263 Page 22 of 24 our rigorous patient-stratified cross-validation demonstrates generalization across individuals within the cohort and our augmentation protocol introduces acoustic variability, these measures provide no evidence of generalization across recording conditions, equipment specifications, or population demographics. The model may have inadvertently learned to recognize signatures of the specific recording setup or demographic characteristics of the Minsk population rather than universal biomarkers of ALS pathology. Clinical deployment of the NeuraSpeech framework would require mandatory validation on geographically and technologically diverse datasets collected with different recording equipment and protocols to establish true diagnostic robustness across real-world clinical environments.

    Neuraspeech: a secure machine learning-blockchain framework for speech-based amyotrophic lateral sclerosis detection · 2026 · DOI

  • The discrepancy between expected and observed age of onset in SOD1 patients compared to sporadic ALS patients suggests that environmental factors may play a significant role, but the mechanisms underlying this relationship remain unclear.

    Dynamic changes in excitability and viability of sporadic and SOD1-related amyotrophic lateral sclerosis iPSC-derived motor neurons · 2026 · DOI

  • The culture system contained a mixed population of neurons and glia, and the proportion of GFAP+ astrocytes was not quantified; the presence of astrocytes may have influenced motor neuron excitability and survival.

    Dynamic changes in excitability and viability of sporadic and SOD1-related amyotrophic lateral sclerosis iPSC-derived motor neurons · 2026 · DOI

  • The findings emphasize the need for further research into the clinical features associated with SOD1 mutations and their potential contributions to SMA-like presentations, refining our understanding of motor neuron disorders.

    Adult-onset spinal muscular atrophy in a patient with SOD1 mutation: case report · 2025 · DOI

  • This multifactorial nature of disease etiology partly explains why, despite intensive research efforts, effective treatments remain elusive and ALS continues to represent an unmet medical need.

    New Treatment Opportunities For Amyotrophic Lateral Sclerosis · 2025 · DOI

  • In the 30 years from gene discovery in 1993 to gene therapy in 2022, there is much that has been learned about therapy development for SOD1 ALS. First and foremost, it is now possible to meaningfully affect the disease course because of the knowledge gained about the cause of disease and an understanding, even if incomplete, of its underlying pathophysiology.

    Amyotrophic lateral sclerosis caused by SOD1 variants: from genetic discovery to disease prevention · 2024 · DOI

  • ALS-related videos on YouTube play a role in raising awareness among the general public of this devastating disease, however, practical information regarding disease management for patients and family is relatively insufficient.

    Amyotrophic lateral sclerosis in social media: Content analysis of YouTube videos · 2022 · DOI

Most-cited papers in Amyotrophic Lateral Sclerosis Research

Most recent work

Find a gap in your own Amyotrophic Lateral Sclerosis Research sub-topic

This page shows what the Amyotrophic Lateral Sclerosis Research literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
50 open questions have been extracted from the limitations and future-work passages of 232 Amyotrophic Lateral Sclerosis Research papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.